Clinical immune‐monitoring strategies for predicting infection risk in solid organ transplantation

Infectious complications remain a leading cause of morbidity and mortality after solid organ transplantation (SOT), and largely depend on the net state of immunosuppression achieved with current regimens. Cytomegalovirus (CMV) is a major opportunistic viral pathogen in this setting. The application of strategies of immunological monitoring in SOT recipients would allow tailoring of immunosuppression and prophylaxis practices according to the individual's actual risk of infection. Immune monitoring may be pathogen‐specific or nonspecific. Nonspecific immune monitoring may rely on either the quantification of peripheral blood biomarkers that reflect the status of a given arm of the immune response (serum immunoglobulins and complement factors, lymphocyte sub‐populations, soluble form of CD30), or on the functional assessment of T‐cell responsiveness (release of intracellular adenosine triphosphate following a mitogenic stimulus). In addition, various methods are currently available for monitoring pathogen‐specific responses, such as CMV‐specific T‐cell‐mediated immune response, based on interferon‐γ release assays, intracellular cytokine staining or main histocompatibility complex‐tetramer technology. This review summarizes the clinical evidence to date supporting the use of these approaches to the post‐transplant immune status, as well as their potential limitations. Intervention studies based on validated strategies for immune monitoring still need to be performed.